"instanceType","id","name","label","uuid:ID","rationale","description"
"StudyDesign","StudyDesign_1","Study Design 1","","6277edcc-b87f-4973-ad30-82037ba5b90e","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","The main design for the study"
